Sugary Drinks Raise Stomach Cancer Risk; Fiber Aids IBS
Prospective U.S. data showed that daily consumption of sugar-sweetened beverages was associated with more than a twofold increased risk of gastric cancer. A randomized trial found no benefit from preoperative high-dose corticosteroids for digestive cancer surgeries. A meta-analysis indicated that fiber supplements, particularly psyllium, can improve clinical responses in irritable bowel syndrome.
The U.S. prospective study linking daily sugar-sweetened beverage consumption to a more than twofold gastric cancer risk adds to a growing body of evidence implicating dietary factors in gastrointestinal malignancies. Separately, a randomized trial found no support for routine preoperative high-dose corticosteroids in elective digestive cancer surgeries, suggesting current practice may warrant reconsideration.
On the management side, a meta-analysis of randomized trials showed fiber supplements, particularly psyllium, can improve clinical responses in irritable bowel syndrome. Additional findings included a 26% lower colorectal cancer mortality among those invited for fecal occult screening over nearly 15 years, and similar three-year cancer risks across advanced IBD therapies.
These findings could influence clinical guidance and public health messaging around modifiable risk factors. If confirmed, the sugary drink–gastric cancer association may strengthen calls for reduced consumption, while the fiber evidence offers a low-cost, accessible option for IBS sufferers. The corticosteroid trial may prompt surgeons to reconsider perioperative protocols, potentially reducing unnecessary interventions. Screening invitation data reinforces the value of population-based colorectal cancer programs, which could shape resource allocation decisions.